Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

PURPOSE: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Gettinger, Scott N., Horn, Leora, Gandhi, Leena, Spigel, David R., Antonia, Scott J., Rizvi, Naiyer A., Powderly, John D., Heist, Rebecca S., Carvajal, Richard D., Jackman, David M., Sequist, Lecia V., Smith, David C., Leming, Philip, Carbone, David P., Pinder-Schenck, Mary C., Topalian, Suzanne L., Hodi, F. Stephen, Sosman, Jeffrey A., Sznol, Mario, McDermott, David F., Pardoll, Drew M., Sankar, Vindira, Ahlers, Christoph M., Salvati, Mark, Wigginton, Jon M., Hellmann, Matthew D., Kollia, Georgia D., Gupta, Ashok K., Brahmer, Julie R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4672027/
https://ncbi.nlm.nih.gov/pubmed/25897158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.3708
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados